SCHEMBL7004262

SCHEMBL7004262

O=[N+]([O-])c1cc(C(F)(F)F)ccc1S(=O)(=O)NCCCCCCNc1nsc2nccn12

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
F13A1 P00488 10/20 0.74
TGM1 P22735 4/20 0.74
MAPT P10636 3/20 0.47
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
POLB P06746 1/20 0.46
GAA P10253 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HTT P42858 1/20 0.45
NFKBIA P25963 2/20 0.42
RELA Q04206 2/20 0.42
SLC40A1 Q9NP59 1/20 0.42
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PARP14 Q460N5 1/20 0.39
MMP2 P08253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7006324 0.85 F13A1 (1.00) F13A1TGM1HTTALDH1A1
SCHEMBL7011955 0.84 F13A1 (0.77) F13A1TGM1MAPTLMNASMN1; SMN2
SCHEMBL7003304 0.82 F13A1 (0.73) F13A1TGM1MAPTGAACYP3A4
SCHEMBL7006423 0.79 F13A1 (0.74) F13A1TGM1SLC40A1
SCHEMBL7008217 0.79 F13A1 (0.75) F13A1TGM1MAPTSMN1; SMN2POLB
SCHEMBL7009101 0.79 F13A1 (0.80) F13A1TGM1LMNASMN1; SMN2HTT
SCHEMBL7008548 0.79 F13A1 (1.00) F13A1TGM1MAPTLMNAPOLB
SCHEMBL7005365 0.78 F13A1 (0.67) F13A1TGM1LMNAALDH1A1
SCHEMBL7009658 0.78 F13A1 (0.67) F13A1TGM1LMNAALDH1A1
SCHEMBL7004951 0.77 F13A1 (1.00) F13A1TGM1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225007-A1 Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases APOTEX INC. 2003-12-04 US disclosed
EP-1348710-A1 Sulfonamide derivatives of 3-substituted imidazo[1,2-D]-1,2,4-thiadiazoles and 3-substituted-[1,2,4]thiadiazolo[4,5-A]benzimidazole as inhibitors of fibrin cross-linking and transglutaminases Apotex Inc. (CA) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225007-A1 Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases PIGS, FGB, SERPINE1 F13A1 14/4885TGM1 7/4885MAPT 4129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.